249 related articles for article (PubMed ID: 21078937)
1. An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans.
Hoot SJ; Smith AR; Brown RP; White TC
Antimicrob Agents Chemother; 2011 Feb; 55(2):940-2. PubMed ID: 21078937
[TBL] [Abstract][Full Text] [Related]
2. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate.
Dunkel N; Liu TT; Barker KS; Homayouni R; Morschhäuser J; Rogers PD
Eukaryot Cell; 2008 Jul; 7(7):1180-90. PubMed ID: 18487346
[TBL] [Abstract][Full Text] [Related]
3. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans.
Heilmann CJ; Schneider S; Barker KS; Rogers PD; Morschhäuser J
Antimicrob Agents Chemother; 2010 Jan; 54(1):353-9. PubMed ID: 19884367
[TBL] [Abstract][Full Text] [Related]
4. UPC2A is required for high-level azole antifungal resistance in Candida glabrata.
Whaley SG; Caudle KE; Vermitsky JP; Chadwick SG; Toner G; Barker KS; Gygax SE; Rogers PD
Antimicrob Agents Chemother; 2014 Aug; 58(8):4543-54. PubMed ID: 24867980
[TBL] [Abstract][Full Text] [Related]
5. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes.
MacPherson S; Akache B; Weber S; De Deken X; Raymond M; Turcotte B
Antimicrob Agents Chemother; 2005 May; 49(5):1745-52. PubMed ID: 15855491
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans.
Flowers SA; Barker KS; Berkow EL; Toner G; Chadwick SG; Gygax SE; Morschhäuser J; Rogers PD
Eukaryot Cell; 2012 Oct; 11(10):1289-99. PubMed ID: 22923048
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals.
Eddouzi J; Parker JE; Vale-Silva LA; Coste A; Ischer F; Kelly S; Manai M; Sanglard D
Antimicrob Agents Chemother; 2013 Jul; 57(7):3182-93. PubMed ID: 23629718
[TBL] [Abstract][Full Text] [Related]
8. Loss of Upc2p-Inducible
Luna-Tapia A; Willems HME; Parker JE; Tournu H; Barker KS; Nishimoto AT; Rogers PD; Kelly SL; Peters BM; Palmer GE
mBio; 2018 May; 9(3):. PubMed ID: 29789366
[TBL] [Abstract][Full Text] [Related]
9. Upc2-mediated mechanisms of azole resistance in
Li J; Aubry L; Brandalise D; Coste AT; Sanglard D; Lamoth F
Microbiol Spectr; 2024 Feb; 12(2):e0352623. PubMed ID: 38206035
[No Abstract] [Full Text] [Related]
10. Rapid detection of ERG11 gene mutations in clinical Candida albicans isolates with reduced susceptibility to fluconazole by rolling circle amplification and DNA sequencing.
Wang H; Kong F; Sorrell TC; Wang B; McNicholas P; Pantarat N; Ellis D; Xiao M; Widmer F; Chen SC
BMC Microbiol; 2009 Aug; 9():167. PubMed ID: 19682357
[TBL] [Abstract][Full Text] [Related]
11. Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance.
Znaidi S; Weber S; Al-Abdin OZ; Bomme P; Saidane S; Drouin S; Lemieux S; De Deken X; Robert F; Raymond M
Eukaryot Cell; 2008 May; 7(5):836-47. PubMed ID: 18390649
[TBL] [Abstract][Full Text] [Related]
12. A newly identified amino acid substitution T123I in the 14α-demethylase (Erg11p) of Candida albicans confers azole resistance.
Wu Y; Gao N; Li C; Gao J; Ying C
FEMS Yeast Res; 2017 May; 17(3):. PubMed ID: 28334124
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China.
Liu JY; Shi C; Wang Y; Li WJ; Zhao Y; Xiang MJ
Res Microbiol; 2015 Apr; 166(3):153-61. PubMed ID: 25748216
[TBL] [Abstract][Full Text] [Related]
14.
Nishimoto AT; Wiederhold NP; Flowers SA; Zhang Q; Kelly SL; Morschhäuser J; Yates CM; Hoekstra WJ; Schotzinger RJ; Garvey EP; Rogers PD
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910896
[TBL] [Abstract][Full Text] [Related]
15. Candida albicans UPC2 is transcriptionally induced in response to antifungal drugs and anaerobicity through Upc2p-dependent and -independent mechanisms.
Hoot SJ; Oliver BG; White TC
Microbiology (Reading); 2008 Sep; 154(Pt 9):2748-2756. PubMed ID: 18757808
[TBL] [Abstract][Full Text] [Related]
16. cis-Acting elements within the Candida albicans ERG11 promoter mediate the azole response through transcription factor Upc2p.
Oliver BG; Song JL; Choiniere JH; White TC
Eukaryot Cell; 2007 Dec; 6(12):2231-9. PubMed ID: 17951521
[TBL] [Abstract][Full Text] [Related]
17. Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and
Nishimoto AT; Zhang Q; Hazlett B; Morschhäuser J; Rogers PD
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833425
[TBL] [Abstract][Full Text] [Related]
18. Reduced susceptibility of Candida albicans clinical isolates to azoles and detection of mutations in the ERG11 gene.
Zhang L; Yang HF; Liu YY; Xu XH; Ye Y; Li JB
Diagn Microbiol Infect Dis; 2013 Dec; 77(4):327-9. PubMed ID: 24070847
[TBL] [Abstract][Full Text] [Related]
19. Mutations and/or Overexpressions of ERG4 and ERG11 Genes in Clinical Azoles-Resistant Isolates of Candida albicans.
Feng W; Yang J; Xi Z; Qiao Z; Lv Y; Wang Y; Ma Y; Wang Y; Cen W
Microb Drug Resist; 2017 Jul; 23(5):563-570. PubMed ID: 27976986
[TBL] [Abstract][Full Text] [Related]
20. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
